Willis K. Samson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Willis K. Samson has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Tonya C. Murphy
Department of Physiology, University of North Dakota School of Medicine, 501 North Columbia Road, Grand Forks, ND 58202-9037, USA
3 shared publicationsZachary T. Resch
Department of Physiology, University of North Dakota School of Medicine, 501 North Columbia Road, Grand Forks, ND 58202-9037, USA
3 shared publicationsJaw-Kang Chang
Phoenix Pharmaceuticals, Mountain View, CA, USA
2 shared publicationsAnn M Bode
1 shared publicationBlake Gosnell
The Neuropsychiatric Research Institute, Fargo, ND, USA
1 shared publicationD Robison
1 shared publication
Latest Publications
- 1 June 1999
- Published by Elsevier in Brain Research
- Vol. 831 (1-2) , 248-253
Cardiovascular regulatory actions of the hypocretins in brain
- 1 June 1999
- Published by Elsevier in Brain Research
- Vol. 831 (1-2) , 248-253
Cardiovascular regulatory actions of the hypocretins in brain
- 1 March 1999
- Published by Annual Reviews in Annual Review of Physiology
- Vol. 61 (1) , 363-389
ADRENOMEDULLIN AND THE CONTROL OF FLUID AND ELECTROLYTE HOMEOSTASIS
▪ Abstract Two potent hypotensive peptides, adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP), are encoded by the adrenomedullin gene. AM stimulates nitric oxide production by endothelial cells, whereas PAMP acts presynaptically to inhibit adrenergic nerves that innervate blood vessels. Complementary, but mechanistically unique, actions also occur in the anterior pituitary gland where both peptides inhibit adrenocorticotropin release. In the adrenal gland both AM and PAMP inhibit potassium and angiotensin II-stimulated aldosterone secretion. Natriuretic and diuretic actions of AM reflect unique actions of the peptide on renal blood flow and tubular function. In the brain AM inhibits water intake and, in a physiologically relevant manner, salt appetite. Both AM and PAMP act in the brain to elevate sympathetic tone, effects that mirror the positive inotropic action of AM in the heart. Cardioprotective actions in the brain and heart may be important counter-regulatory actions that buffer the extreme hypotensive actions of the peptides when released in sepsis. Thus the biologic actions of the proadrenomedullin-derived peptides seem well coordinated to contribute to the physiologic regulation of volume and electrolyte homeostasis.
- 1 March 1999
- Published by Annual Reviews in Annual Review of Physiology
- Vol. 61 (1) , 363-389
ADRENOMEDULLIN AND THE CONTROL OF FLUID AND ELECTROLYTE HOMEOSTASIS
▪ Abstract Two potent hypotensive peptides, adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP), are encoded by the adrenomedullin gene. AM stimulates nitric oxide production by endothelial cells, whereas PAMP acts presynaptically to inhibit adrenergic nerves that innervate blood vessels. Complementary, but mechanistically unique, actions also occur in the anterior pituitary gland where both peptides inhibit adrenocorticotropin release. In the adrenal gland both AM and PAMP inhibit potassium and angiotensin II-stimulated aldosterone secretion. Natriuretic and diuretic actions of AM reflect unique actions of the peptide on renal blood flow and tubular function. In the brain AM inhibits water intake and, in a physiologically relevant manner, salt appetite. Both AM and PAMP act in the brain to elevate sympathetic tone, effects that mirror the positive inotropic action of AM in the heart. Cardioprotective actions in the brain and heart may be important counter-regulatory actions that buffer the extreme hypotensive actions of the peptides when released in sepsis. Thus the biologic actions of the proadrenomedullin-derived peptides seem well coordinated to contribute to the physiologic regulation of volume and electrolyte homeostasis.
- 1 February 1999
- Published by Elsevier in Brain Research
- Vol. 818 (1) , 164-167
Antisense oligonucleotide treatment reveals a physiologically relevant role for adrenomedullin gene products in sodium intake
- 1 February 1999
- Published by Elsevier in Brain Research
- Vol. 818 (1) , 164-167
Antisense oligonucleotide treatment reveals a physiologically relevant role for adrenomedullin gene products in sodium intake
- 1 January 1998
- Published by Springer Nature in Endocrine
- Vol. 9 (3) , 289-292
Gender-Biased Activity of the Novel Prolactin Releasing Peptides: Comparison with Thyrotropin Releasing Hormone Reveals Only Pharmacologic Effects
The prolactin- (PRL) releasing activities of the newly described PRL-releasing peptides (PrRPs) were compared to that of thyrotropin-releasing hormone (TRH) in dispersed, rat anterior pituitary cell cultures. A dose-related stimulation of PRL release by TRH was observed in cells harvested from both intact male and random cycle female pituitary donors. The minimum effective dose of TRH ranged from 1 to 10 nM. Neither PrRP-20 nor PrRP-31 significantly altered PRL secretion in cells from male donors even at doses as high as 1 µM. In cells harvested from females, only the highest doses of PrRP-20 and PrRP-31 tested (0.1 and 1.0 µM) significantly stimulated PRL secretion. The PRL-releasing action of TRH was observed already at 15 min of incubation, whereas those of PrRP-20 and PrRP-31 appeared only after 1 and 2 h of incubation, and the magnitude of PRL release in the presence of 1 µM PrRPs was significantly less than that of a similar dose of TRH. These data do not suggest a physiologically relevant role for the PrRPs in the neuroendocrine regulation of PRL secretion in intact male and nonlactating, random-cycle female rats.
- 1 January 1998
- Published by Springer Nature in Endocrine
- Vol. 9 (3) , 289-292
Gender-Biased Activity of the Novel Prolactin Releasing Peptides: Comparison with Thyrotropin Releasing Hormone Reveals Only Pharmacologic Effects
The prolactin- (PRL) releasing activities of the newly described PRL-releasing peptides (PrRPs) were compared to that of thyrotropin-releasing hormone (TRH) in dispersed, rat anterior pituitary cell cultures. A dose-related stimulation of PRL release by TRH was observed in cells harvested from both intact male and random cycle female pituitary donors. The minimum effective dose of TRH ranged from 1 to 10 nM. Neither PrRP-20 nor PrRP-31 significantly altered PRL secretion in cells from male donors even at doses as high as 1 µM. In cells harvested from females, only the highest doses of PrRP-20 and PrRP-31 tested (0.1 and 1.0 µM) significantly stimulated PRL secretion. The PRL-releasing action of TRH was observed already at 15 min of incubation, whereas those of PrRP-20 and PrRP-31 appeared only after 1 and 2 h of incubation, and the magnitude of PRL release in the presence of 1 µM PrRPs was significantly less than that of a similar dose of TRH. These data do not suggest a physiologically relevant role for the PrRPs in the neuroendocrine regulation of PRL secretion in intact male and nonlactating, random-cycle female rats.
- 1 January 1998
- Published by Springer Nature in Endocrine
- Vol. 9 (3) , 269-272
Proadrenomedullin N-Terminal 20 Peptide Inhibits Adrenocorticotropin Secretion from Cultured Pituitary Cells, Possibly via Activation of a Potassium Channel
Preproadrenomedullin is processed into at least two biologically active peptides, adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP). Both peptides are hypotensive; however, they exert this action via differing mechanisms. In pituitary cells in culture, both basal and releasing factor-stimulated adrenocorticotropin (ACTH) secretion is inhibited by AM. Here we report that basal, but not stimulated, ACTH secretion from cultured rat pituitary cells is also inhibited by PAMP. The effect is dose-related, occurs in a physiologically relevant dose range that is similar to that of AM, and is blocked by the potassium channel blocker, glybenclamide. The failure of glybenclamide to inhibit AM's effects on ACTH secretion indicates that in pituitary, as in other tissues, these two products of the same prohormone can exert similar biologic activity, although via differing mechanisms.
- 1 January 1998
- Published by Springer Nature in Endocrine
- Vol. 9 (3) , 269-272
Proadrenomedullin N-Terminal 20 Peptide Inhibits Adrenocorticotropin Secretion from Cultured Pituitary Cells, Possibly via Activation of a Potassium Channel
Preproadrenomedullin is processed into at least two biologically active peptides, adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP). Both peptides are hypotensive; however, they exert this action via differing mechanisms. In pituitary cells in culture, both basal and releasing factor-stimulated adrenocorticotropin (ACTH) secretion is inhibited by AM. Here we report that basal, but not stimulated, ACTH secretion from cultured rat pituitary cells is also inhibited by PAMP. The effect is dose-related, occurs in a physiologically relevant dose range that is similar to that of AM, and is blocked by the potassium channel blocker, glybenclamide. The failure of glybenclamide to inhibit AM's effects on ACTH secretion indicates that in pituitary, as in other tissues, these two products of the same prohormone can exert similar biologic activity, although via differing mechanisms.
- 1 November 1996
- Published by The Endocrine Society in Endocrinology
- Vol. 137 (11) , 5182-5185
A 35 amino acid fragment of leptin inhibits feeding in the rat.
Peptide fragments of the larger 167 amino acid obesity gene related peptide (OBGRP), leptin, were tested for their ability to inhibit feeding in the rat. The C-terminal fragment, OBGRP 116-167 exerted only minimal inhibition of feeding when administered into the lateral cerebroventricle. No alteration in feeding was observed following administration of OBGRP 57-92. We hypothesized that the satiety effects of leptin reside in the N-terminal region of the peptide sequence. Significant, dose-related, and reversible inhibition of food intake was observed following central administration of the 35 amino acid fragment OBGRP 22-56. These results suggest that a small, readily synthesized fragment of the 167 amino acid peptide leptin may exert physiologically relevant satiety effects in brain revealing an endocrine feedback mechanism by which the adipocyte may modulate hypothalamic function.
- 1 November 1996
- Published by The Endocrine Society in Endocrinology
- Vol. 137 (11) , 5182-5185
A 35 amino acid fragment of leptin inhibits feeding in the rat.
Peptide fragments of the larger 167 amino acid obesity gene related peptide (OBGRP), leptin, were tested for their ability to inhibit feeding in the rat. The C-terminal fragment, OBGRP 116-167 exerted only minimal inhibition of feeding when administered into the lateral cerebroventricle. No alteration in feeding was observed following administration of OBGRP 57-92. We hypothesized that the satiety effects of leptin reside in the N-terminal region of the peptide sequence. Significant, dose-related, and reversible inhibition of food intake was observed following central administration of the 35 amino acid fragment OBGRP 22-56. These results suggest that a small, readily synthesized fragment of the 167 amino acid peptide leptin may exert physiologically relevant satiety effects in brain revealing an endocrine feedback mechanism by which the adipocyte may modulate hypothalamic function.